ImaRx Therapeutics Inc.

Tucson, Ariz. • 520-770-1259 •

Ticker and Exchange: IMRX: Nasdaq

Filing Range: 3M shares @ $6.50 to $7.50

Offering Price: $5.00

Close on First Day: $4.79

Offering Size: $15.00M

Shares Outstanding: 10,007,868

Underwriter: Maxim Group

Co-manager: I-Bankers Securities Inc

Company Counsel: DLA Piper

Manager Counsel: Richardson & Patel

Auditor: Ernst & Young LLP

Market Capitalization on 7/31/07: $47.9M

Close on 7/31/07: $4.79


Operates as a biopharmaceutical company focused on vascular disorders. The company’s proprietary microbubble technology treats vascular occlusions, or blood vessel blockages, as well as the resulting ischemia, which is tissue damage caused by a reduced supply of oxygen. ImaRx Therapeutics is likewise focused on products approved by the U.S. Food and Drug Administration for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. Competitors include Genentech Inc., Concentric Medical Inc., Edwards Lifesciences, Possis Medical Inc., EKOS Corp., OmniSonics Medical Technologies Inc.


Coronado Venture Fund, Boston Scientific Corp. and Solstice Capital.

Source: Thomson Financial